Understand the source comparison
Follistatin-344 Dosage Guide: Research Protocol Comparison
The following table summarizes dosing protocols from peer-reviewed research, contrasting study design, administration parameters, and observed outcomes to guide experimental protocol development. Rodent model (Journal of Clinical Investigation, 2009) 200–300mc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table summarizes dosing protocols from peer-reviewed research, contrasting study design, administration parameters, and observed outcomes to guide experimental protocol development.
- Rodent model (Journal of Clinical Investigation, 2009)
- 200–300mcg/kg
- Twice daily (12-hour intervals)
- 8 weeks
- 27–35% increase in muscle mass; enhanced satellite cell activation
- Subcutaneous injection; myostatin suppression confirmed via Western blot
- Primate model (Molecular Therapy, 2011)
- 3mg/kg weekly (~250mcg/day equivalent)
- Single weekly injection
- 12 weeks
- Significant grip strength increase; muscle fiber diameter +18%
- No adverse histological findings; weekly dosing showed sustained suppression
- In vitro human myoblast cultures (multiple studies)
- 100–500ng/ml culture concentration
- Continuous exposure
- 72–96 hours
- Dose-dependent myotube formation; peak response 200–300ng/ml
- Translates to ~100–200mcg systemic dose extrapolation
- Veterinary application (equine)
- 100mcg twice daily
- Twice daily
- 4–6 weeks
- Lean mass increase in performance horses; no reported adverse events
- Conservative dosing; widely used in performance animal research